Transfusion-transmitted infections are the most commonly encountered complications in transfusion practice. Serological markers for hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV) and Treponema pallidum were screened in blood banks routinely. These tests are obligatory for transfusion safety and may give an idea about the seropositivity rates of a specific region. In this study, the results of 29,049 volunteer blood donors who were admitted to Blood Center of Kocaeli University Hospital between January 1999 to January 2004, have been retrospectively evaluated. HBsAg, anti-HCV and anti-HIV-1/2 were screened by microparticle enzyme immunoassay (MEIA), and syphilis antibodies were screened by rapid plasma reagin (RPR) test in the Blood Center Laboratory. The seropositivity rates for HBsAg, anti-HCV and RPR were found as 2.3%, 0.37% and 0.02%, respectively. Eight donors were found seropositive for anti-HIV-1/2, but they were all accepted as false positive results, since the western blot confirmation tests were all negative.
Download full-text PDF |
Source |
---|
Gastroenterology
February 2025
Section of Gastroenterology and Hepatology, Veterans Affairs Northeast Ohio Health Care System, Cleveland, Ohio; Division of Gastroenterology and Hepatology, Case Western Reserve University, Cleveland, Ohio.
Background & Aims: Hepatitis B reactivation (HBVr) can occur due to a variety of immune-modulating exposures, including multiple drug classes and disease states. Antiviral prophylaxis can be effective in mitigating the risk of HBVr. In select cases, clinical monitoring without antiviral prophylaxis is sufficient for managing the risk of HBVr.
View Article and Find Full Text PDFVirus Res
January 2025
Medical Research Center, Yuebei People's Hospital, Shantou University Medical College, 512025, Shaoguan, China; Shenzhen Immuthy Biotech Co., Ltd, 518107, Shenzhen, Guangdong, China. Electronic address:
Hepatitis B virus (HBV) represents one of the major pathogenic factor that leads to chronic liver diseases and the development of hepatocellular carcinoma (HCC). The currently approved anti-HBV drugs cannot eradicate the virus or block the development of HCC. HBV nucleocapsid consists of the hepatitis B core antigen (HBcAg) and the HBV relaxed-circular partially double-stranded DNA (rcDNA), indispensable in virus replication.
View Article and Find Full Text PDFJ Biol Chem
January 2025
Institute of Virology, Philipps University Marburg, Marburg, Germany. Electronic address:
Orthoflaviviruses are emerging arthropod-borne pathogens whose replication cycle is tightly linked to host lipid metabolism. Previous lipidomic studies demonstrated that infection with the closely related hepatitis C virus (HCV) changes the fatty acid (FA) profile of several lipid classes. Lipids in HCV-infected cells had more very long-chain and desaturated FAs and viral replication relied on functional FA elongation and desaturation.
View Article and Find Full Text PDFAm J Transplant
January 2025
Department of Pediatrics, University of Wisconsin Madison, Madison, WI.
Hepatitis C virus (HCV) infection is increasing in prevalence due to the growing opioid epidemic; however, its impact on pediatric kidney transplantation is unknown. This study compared kidney transplant outcomes between HCV-positive and propensity-score-weighted HCV-negative pediatric recipients. It also examined HCV-positive kidney utilization for pediatric transplantation in the United States.
View Article and Find Full Text PDFDiagn Microbiol Infect Dis
January 2025
Department of Human Parasitology, School of Basic Medical Science, Hubei University of Medicine, Shiyan, China. Electronic address:
Objective: Transfusion-transmissible infections (TTIs) are severe threats to blood safety and public health. A retrospective study of blood donor records from 2015 to 2019 in Shiyan, China, was conducted.
Methods: TTI prevalence was analyzed using ELISA, RT-PCR, and demographic data.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!